header logo image


Page 277«..1020..276277278279..290300..»

Fuse Medical Ranked Number 43 Fastest Growing Company in North America on Deloitte’s 2020 Technology Fast 500 – Business Wire

December 4th, 2020 12:24 am

RICHARDSON, Texas--(BUSINESS WIRE)--Fuse Medical, Inc., (OTCPK: FZMD), an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced that it ranked number 43 on Deloittes Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. During the selected period Fuses revenue grew 3,935%.

Fuse Medicals Chief Executive Officer, Christopher C. Reeg, said, We are honored to be ranked on Deloittes Technology Fast 500 for the third year in a row, especially during these trying times with the COVID-19 pandemic. It is a privilege to be included with other fast-growing, innovative companies that are rapidly becoming leaders in their market sectors. This recognition further validates Fuses continued commitment to new product development and commercialization, while adding value to the healthcare system.

Mohana Dissanayake, Partner, Deloitte & Touche LLP commented, Each year the Technology Fast 500 listing validates how important technology innovation is to our daily lives. It was interesting to see this year that while software companies continued to dominate, biotech companies rose to the top of the winners list for the first time, demonstrating that new categories of innovation are accelerating in the pursuit of making life easier, safer, and more productive. We extend our congratulations to these well-deserved winnerswho all embody a spirit of curiosity, and a never-ending commitment to making technology advancements possible.

Fuse Medical moved up 46 spots on the winners list from where it previously ranked last year at 89. Overall, 2020 Technology Fast 500 companies achieved revenue growth ranging from 175 percent to 106,508 percent from 2016 to 2019, with median growth of 450 percent.

For more than 25 years, weve been honoring companies that define the cutting edge and this years Technology Fast 500 list is proof positive that technology from software and digital media platforms, to biotech truly does permeate so many facets of our lives, said Paul Silverglate, vice chairman, Deloitte LLP and U.S. technology sector leader. We congratulate this years winners, especially during a time when innovation is needed more than ever to address the monumental challenges posed by the pandemic.

About Deloittes 2019 Technology Fast 500

Now in its 26th year, Deloittes Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies both public and private in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2016 to 2019.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Fuse Medical, Inc.

Fuse is an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace. We provide a comprehensive portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as, degenerative and deformity spine, orthobiologics and regenerative medicine products. For more information about the Company, or if youre interested in becoming a distributor of any Fuses products, please contact us at info@fusemedical.com or visit: http://www.fusemedical.com.

Forward Looking Statements

Certain statements in this press release, constitute forward-looking statements within the meaning of the federal securities laws. Words such as may, might, will, should, believe, expect, anticipate, estimate, continue, predict, forecast, project, plan, intend, or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Companys filings with the Securities and Exchange Commission; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.

Visit link:
Fuse Medical Ranked Number 43 Fastest Growing Company in North America on Deloitte's 2020 Technology Fast 500 - Business Wire

Read More...

Regenerative Medicine Market 2020 Global Size, Industry Applications, Sales Revenue, Share, Recent Trends, Competitive Landscape, With Regional…

December 4th, 2020 12:24 am

Global Regenerative Medicine Market report, published by Adroit Market Research, is an extensive compilation of the essential aspects of the global Regenerative Medicine market, assessed thoroughly by our team of researchers. The market intelligence report offers insightful data and information relevant to the market to acquaint the readers with the lucrative growth prospects existing in this industry, eventually helping them formulate effective business strategies. The global Regenerative Medicine market report has been methodically curated using industry-verified data to offer information concerned with the leading manufacturers and suppliers engaged in this sector. It further focuses on their pricing analysis, gross revenue, product portfolio, sales network & distribution channels, profit margins, and financial standing. Therefore, the latest research document includes competitive analysis, key market players, crucial industry-related facts & figures, sales revenue, product prices, gross margins, market shares, business strategies, dominant regions, and key developments.

Top Leading Key Players are:

Integra LifeSciences Corporation; MiMedx Group, Inc.; AstraZeneca; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Pfizer Inc.; and Baxter.

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/52?utm_source=PT

Regenerative Medicine Market analysis covering the period 2020 to 2025. Industry coverage includes production capacities, trends and industry drivers. Market coverage includes international trade, segmental drivers, volumes, market prices and market values. The key focus of the report is a detailed look at historic, current and projected future volumes in the primary market segments. The report also presents a thorough qualitative and quantitative data pertaining to the projected impact of these factors on markets future growth prospects. With the inclusive market data concerning the key elements and segments of the global Regenerative Medicine market that can influence the growth prospects of the market, the report makes for a highly informative document. The Regenerative Medicine Market report displays the production, consumption, revenue, gross margin, cost, market share, CAGR, and market impacting variables of the Regenerative Medicine industry and forecast to 2025, from 2020.

For in-depth analysis and thorough understanding, the report presents a demand for individual segment in each region. It demonstrates various segments B2B, B2C, C2C and sub-segments Manufacturing, Consumer Goods, Retail, Automotive, Food and Beverage, Other of the global Regenerative Medicine market. The global Regenerative Medicine market report explains in-depth about the quantitative as well as the qualitative scenario of the market. The global Regenerative Medicine market report delivers the precise analytical information that explains the future growth trend to be followed by the global Regenerative Medicine market, based on the past and current situation of the market. In addition, the global Regenerative Medicine market report delivers concise information about the federal regulations and policies that may indirectly affect market growth as well as the financial state. The situation of the global market at the global and regional level is also described in the global Regenerative Medicine market report through geographical segmentation.

Browse complete Regenerative Medicine market report description and TOC @ https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market?utm_source=PT

The research on the Regenerative Medicine market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Regenerative Medicine market on the basis of end user, product type, application, and demography for the forecast period [emailprotected] Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics. This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Regenerative Medicine market.

Regenerative Medicine Market research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers, and challenges. The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used expert techniques for analyzing the Regenerative Medicine Market; it also offers an examination of the global market. To make the report more potent and easy to understand, it consists of infographics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

The research report on the global Regenerative Medicine market offers a comprehensive analysis, synthesis, and interpretation of data gathered about the Regenerative Medicine market from the number of reliable sources. In addition, the information has analyzed with the help of primary as well as secondary research methodologies to offer a holistic view of the target market. Likewise, the Regenerative Medicine market report offers an in-house analysis of global economic conditions and related economic factors and indicators to evaluate their impact on the Regenerative Medicine market historically. The report provides a broad segmentation of the market by categorizing the market into application, type, and geographical regions. The Regenerative Medicine market report delivers the growth prospects as well as the current scenario of the market. In addition, to assess the market size, the global Regenerative Medicine market report offers a brief outlook of the market by synthesis, study, and addition of data form the number of sources.

For More Information or Query or Customization Before Buying, Visit at @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52?utm_source=PT

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more here:
Regenerative Medicine Market 2020 Global Size, Industry Applications, Sales Revenue, Share, Recent Trends, Competitive Landscape, With Regional...

Read More...

Exosome Therapeutic Market 2020-2026 Thriving Worldwide || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron…

December 4th, 2020 12:23 am

In Exosome Therapeutic Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and charts which eases the understanding of facts and figures. A proficient data and excellent forecasting techniques used in this report are synonymous with accurateness and correctness. Exosome Therapeutic Market report is a painstaking analysis of existing scenario of the market which covers several market dynamics. The market study of this global Exosome Therapeutic Market business report takes into consideration market attractiveness analysis where each segment is benchmarked based on its market size, growth rate & general attractiveness.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Read the original here:
Exosome Therapeutic Market 2020-2026 Thriving Worldwide || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron...

Read More...

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

December 4th, 2020 12:21 am

WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020.

More:
Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

Read More...

BioAge Raises $90M to Treat Aging and Age-related Diseases

December 4th, 2020 12:21 am

Proceeds will support advancement of the company’s pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging

See the rest here:
BioAge Raises $90M to Treat Aging and Age-related Diseases

Read More...

CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium

December 4th, 2020 12:21 am

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced two poster presentations at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) taking place from December 8-11, 2020. Abstracts are available to the public online on the SABCS website at www.sabcs.org.

Original post:
CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium

Read More...

 Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology…

December 4th, 2020 12:21 am

Phase 2 expansion cohort data supports ongoing Phase 3 trial Phase 2 expansion cohort data supports ongoing Phase 3 trial

Go here to read the rest:
 Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology...

Read More...

Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research

December 4th, 2020 12:21 am

Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials

Read the rest here:
Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research

Read More...

Taconic Biosciences Expands Innovative ExpressMODEL® Portfolio

December 4th, 2020 12:21 am

New Random Integration Transgenic Animal Model Generation Solution Available New Random Integration Transgenic Animal Model Generation Solution Available

Read more:
Taconic Biosciences Expands Innovative ExpressMODEL® Portfolio

Read More...

AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19…

December 4th, 2020 12:21 am

SAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or the “Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test (the “Test”) for the detection of SARS?CoV-2 neutralizing antibodies. This application marks AXIM’s fourth COVID-19 neutralizing antibody-focused patent application. The Company heavily focuses its resources on advancing research on what it believes will soon become the most prevalent need in the post-vaccine COVID-19 fight, the need to know levels of neutralizing antibodies in longitudinal studies of vaccine response.

See original here:
AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19...

Read More...

Parexel Named Best Contract Research Organization by Scrip

December 4th, 2020 12:21 am

Company recognized for innovative and effective use of real-world data and flexible trial designs Company recognized for innovative and effective use of real-world data and flexible trial designs

Read the original here:
Parexel Named Best Contract Research Organization by Scrip

Read More...

Intrivo Diagnostics Inks National Distribution Agreements with Concordance Healthcare Solutions and NDC for Access Bio CareStart™ COVID-19 Tests

December 4th, 2020 12:21 am

Major supply chain agreements will ensure broad access to rapid testing solutions for patients and healthcare providers across US

Read more:
Intrivo Diagnostics Inks National Distribution Agreements with Concordance Healthcare Solutions and NDC for Access Bio CareStart™ COVID-19 Tests

Read More...

Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer’s Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference

December 4th, 2020 12:21 am

BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020.

The rest is here:
Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference

Read More...

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal…

December 4th, 2020 12:21 am

NEW YORK and LONDON, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces the publication of the results of a two-year research collaboration with the University College of London (UCL) Institute of Ophthalmology. The results showed that the therapeutic intravitreal (IVT) administration of long-acting nomacopan mitigated both the severity and progress of retinal damage in two models of autoimmune uveitis, a severe inflammatory eye disease where steroids are the primary treatment option. In addition, results showed the presence of inflammatory cells expressing both complement C5 and LTB4 receptors in retinal tissue from donor patients with uveitis as compared to healthy donor eyes.

Originally posted here:
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal...

Read More...

Tauriga Sciences, Inc. Introduces its Product Line of CBD Infused Bath Bombs Under the Tauri-Gum Brand

December 4th, 2020 12:21 am

Read the original:
Tauriga Sciences, Inc. Introduces its Product Line of CBD Infused Bath Bombs Under the Tauri-Gum Brand

Read More...

Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

December 4th, 2020 12:21 am

Continue reading here:
Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

Read More...

OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients…

December 4th, 2020 12:21 am

NANTES, France, Dec. 03, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), and Nantes University Hospital (CHU de Nantes) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethics Committee (CPP) approved the initiation of a Phase 1/2 trial evaluating first administration of FR104, a monoclonal antibody CD28 antagonist, in patients undergoing renal transplant. This study will be conducted as part of a collaboration agreement between OSE Immunotherapeutics and the University Hospital of Nantes.

See more here:
OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients...

Read More...

Issuance of a 4th tranche of €1.5 million of notes convertible into new shares

December 4th, 2020 12:21 am

Continue reading here:
Issuance of a 4th tranche of €1.5 million of notes convertible into new shares

Read More...

Tauriga Sciences Inc. Fully Repays and Retires $88,333.00 Face Value 8.00% Convertible Debenture Issued on May 18, 2020

December 4th, 2020 12:21 am

Read more:
Tauriga Sciences Inc. Fully Repays and Retires $88,333.00 Face Value 8.00% Convertible Debenture Issued on May 18, 2020

Read More...

Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs

December 4th, 2020 12:21 am

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company’s systemic complement regulator programs on Monday, December 14, 2020 at 12:00 pm Eastern Time.

Read the original here:
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs

Read More...

Page 277«..1020..276277278279..290300..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick